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 ABSTRACT 
Background. Large-scale genetic studies have reported several loci associated with 
specific disorders involving uveitis. Our aim was to identify genetic risk factors that 
might predispose to uveitis per se, independent of the clinical diagnosis, by performing 
a dense genotyping of immune-related loci. 
Methods. 613 cases and 3,693 unaffected controls from three European case/control 
sets were genotyped using the Immunochip array. Only patients with non-infectious 
non-anterior uveitis and without systemic features were selected. To perform a more 
comprehensive analysis of the human leucocyte antigen (HLA) region, single-
nucleotide polymorphisms (SNPs), classical alleles and polymorphic amino acid 
variants were obtained via imputation. A meta-analysis combining the three 
case/control sets was conducted by the inverse variance method. 
Results. The highest peak belonged to the HLA region. A more detailed analysis of this 
signal evidenced a strong association between the classical allele HLA-A*2902 and 
birdshot chorioretinopathy (p=3.21E-35, OR=50.95). An omnibus test yielded HLA-A 62 
and 63 as relevant amino acid positions for this disease. In patients with intermediate 
and posterior uveitis, the strongest associations belonged to the rs7197 polymorphism, 
within HLA-DRA (p=2.07E-11, OR=1.99), and the HLA-DR15 haplotype (DRB1*1501: 
p=1.16E-10, OR=2.08; DQA1*0102: p=4.37E-09, OR=1.77; DQB1*0602: p=7.26E-10, 
OR=2.02). Outside the HLA region, the MAP4K4/IL1R2 locus reached statistical 
significance (rs7608679: p=8.38E-07, OR=1.42). Suggestive associations were found 
at five other loci. 
Conclusions. We have further interrogated the association between the HLA region and 
non-infectious non-anterior uveitis. In addition, we have identified a new non-HLA 
susceptibility factor and proposed additional risk loci with putative roles in this complex 
condition. 
 
  
KEYWORDS: non-infectious uveitis, non-anterior uveitis, human leukocyte antigen, 
meta-analysis, Immunochip. 
INTRODUCTION 
Non-infectious uveitis is an immune-mediated condition characterized by intraocular 
inflammation, which mainly affects the uveal tract but also adjacent structures, 
including the retina and its vessels, the vitreous and the optic nerve.1 This term 
comprises a heterogeneous group of disorders diagnosed according to their clinical 
phenotype that may be confined to the eye or associated with systemic manifestations. 
Based on the location of the inflammation, uveitis can be classified as anterior, 
posterior, intermediate and panuveitis.2 While anterior uveitis has the best visual 
prognosis, non-anterior uveitis patients have a greater risk of permanent vision loss, 
and often require systemic immunosuppressive therapy.3 Nowadays, non-infectious 
uveitis is considered a major cause of visual impairment in the working age population, 
which is responsible for up to 10% of cases of blindness in developed countries.4   
In recent years, there have been substantial advances in our understanding of the 
pathogenic mechanisms leading to non-infectious uveitis.5 Although the precise 
pathogenesis remains unclear, accumulating evidence points to the interplay between 
a complex genetic background together with a deregulated immune response in its 
development. In this regard, large-scale genetic studies have been performed in 
several systemic diseases associated with uveitis, including Behçet’s disease (BD),6-12 
Vogt-Koyanagi-Harada syndrome (VKH),13 and sarcoidosis,14-19 as well as in 
inflammatory disorders confined to the eye, such as birdshot chorioretinopathy 
(BSCR).20 This approach has identified several genetic risk loci, mainly 
immune/inflammatory response genes and genes of the human leukocyte antigen 
(HLA) region, many of which (such as IL23R, STAT4 or ERAP1/ERAP2) are shared by 
the different uveitic syndromes as well as by other immune-mediated diseases. 
All large-scale genotyping scans published to date have investigated specific systemic 
syndromes without considering the shared genetic determinants that might predispose 
to uveitis per se, independent of the clinical diagnosis. Therefore, to further discover 
the genetic component of non-infectious uveitis, we decided to perform a dense 
genotyping of immune-related loci using the Immunochip platform in patients with non-
infectious non-anterior uveitis without systemic features. 
 
 
METHODS 
Study population 
Three independent case/control sets of European ancestry, 360 cases and 1517 
unaffected controls from Spain, 142 cases and 1173 unaffected controls from the 
Netherlands and 111 cases and 1003 unaffected controls from the United Kingdom 
(UK) were included in the study. Spanish and British cohorts have been used in 
previous association studies.21 22 Only patients diagnosed with non-infectious and non-
anterior uveitis (the most severe form of uveitis) were selected. In addition, to avoid the 
identification of signals associated with other clinical manifestations, a total of 91 
patients with uveitis related to systemic diseases (including BD, sarcoidosis, systemic 
lupus erythematosus (SLE), ulcerative colitis, multiple sclerosis, psoriasis, Sjögren's 
syndrome and polymyalgia rheumatica), except VKH, were excluded from the study. 
VKH was included considering that uveitis appears in 100% of the patients, with or 
without systemic involvement. Non-anterior uveitis patients were classified according to 
the anatomical location of the inflammation as posterior uveitis, intermediate uveitis 
and panuveitis. Informed written consent from all participants and approval from the 
local ethical committees were obtained in accordance with the tenets of the Declaration 
of Helsinki. Supplementary Table 1 shows the main characteristics of the case 
cohorts included in the study. 
 
Genotyping 
Genomic DNA was extracted from saliva samples or whole blood by standard methods. 
The genotyping was performed at a single center on the Illumina iScan system with the 
Immunochip platform, which allows a dense analysis of single-nucleotide 
polymorphisms (SNPs), rare variants, and insertion/deletion (indel) polymorphisms. All 
the Spanish samples (cases and controls) as well as unaffected subjects from the 
Netherlands and the UK were genotyped using the HumanImmunov1.0 BeadChip 
(196,524 genetic markers), whereas uveitis samples from the Netherlands and the UK 
were genotyped using the Infinium ImmunoArray-24 v2.0 BeadChip (253,702 genetic 
markers). Genetic variants included in both platforms overlap by 80%. 
 
Quality control and imputation 
Data quality control was performed for each sample set separately prior to imputation. 
SNPs and subjects with successful call rates lower than 98% and 95%, respectively, 
were removed using PLINK v.1.7.23 SNPs with minor allele frequencies lower than 0.01 
and those that were not in Hardy-Weinberg equilibrium (HWE; p < 0.001) were also 
excluded. In addition, one subject per duplicate pair and per pair of first-degree 
relatives was also removed via the Genome function in PLINK v.1.7 with a Pi-HAT 
threshold of 0.4. 
IMPUTE v.2. software was used to perform imputations,24 with The 1000 Genomes 
Phase 3 as reference panel.25 Imputed data were subsequently subjected to stringent 
quality filters inPLINK v.1.7; i.e., individuals who generated genotypes <98% were 
removed, and SNPs with call rates <95% and those that deviated from HWE (p < 
0.001) were also discarded. Principal-component (PC) analyses were performed to 
identify and exclude outliers based on their ethnicity in PLINK v.1.7 and the gcta64 and 
R-base under GNU Public license v.2. With this software, we calculated the ten first 
PCs using the markers informative of ancestry that were included in the Immunochip. 
Those subjects showing more than four standard deviations from the cluster centroids 
were excluded as outliers. 
 
Imputation of the HLA region 
HLA imputation was performed for 8,961 common SNPs, representing classical HLA 
alleles, amino acids, and SNPs, across the extended major histocompatibility complex 
region. We used the SNP2HLA method with the Beagle software package26 and a 
reference panel collected by the Type 1 Diabetes Genetics Consortium comprised of 
5,225 individuals of European origin.27 
 Statistical analysis 
The statistical analyses were performed with PLINK v.1.7 and R. First, each 
case/control cohort was independently analyzed by logistic regression on the best-
guess genotypes (>0.9 probability) assuming an additive model with the first ten PCs 
as covariates. Subsequently, the three case/control sets were combined by inverse 
variance weighted fixed effects meta-analysis. Heterogeneity of the ORs across studies 
was estimated by Cochran’s Q and I2 tests. The presence of independent effects was 
examined using a stepwise logistic regression by conditioning on a lead SNP, the first 
ten PCs and the country of origin as covariates. 
For the HLA region, an omnibus association test28 was also performed to determine the 
influence of the polymorphic amino acid positions on disease susceptibility. For each 
amino acid position, a null generalized linear model, including the first ten PCs and the 
country of origin as covariates, was built and compared with an alternative model, 
including the same variables and all the possible alleles in the analyzed amino acid 
positions, by a likelihood ratio test (LRT). Additionally, we also conducted conditional 
analyses controlling by the most associated positions by including them as covariates 
in the models.  
The Manhattan plots were obtained with an in-house modification of the R script written 
by Stephen Turner. Results of the imputed regions were plotted using the on line tool 
LocusZoom v.1.133 (http://locuszoom.sph.umich.edu/locuszoom/). 
Contrary to genome-wide association studies (GWASs), the Immunochip platform is 
not based on SNPs tagging the whole genome, but on a fine mapping of candidate 
disease-associated loci. Thus, it has been proposed that, since tests are correlated, 
using the strict genome-wide significance threshold (5x10-8) could be an over 
correction.29 Taking this into account, we estimated the appropriate Bonferroni-based 
statistical threshold for our study using the Genetic type 1 Error Calculator (GEC) 
software,30 which calculates the effective number of independent tests. A significant 
threshold of 1.14x10-6 was obtained and, therefore, p-values below this threshold were 
considered as statistically significant. A suggestive tier of association (2.29x10-5) was 
also calculated using this software. 
The statistical power of the study was estimated by using CaTS Power Calculator for 
Genetic Studies,31 setting the significance level at 1.14x10-6 (Supplementary Table 2). 
 
Functional annotation 
After meta-analysis, the associated SNPs, as well as those in high linkage 
disequilibirum (LD) (r2 > 0.8) with them (using the European populations of the 1000 
Genomes Project Phase III data), were interrogated for potential regulatory function. 
The HaploReg v4.1 database32 was used to evaluate whether they were located within 
regulatory DNA elements, including regions of DNAase hypersensitivity, binding sites 
of transcription factors or chromatin marks. Their effect on gene expression was also 
explored using HaploReg v4.1 by means of in silico expression quantitative trait locus 
(eQTL) analysis. 
RESULTS 
Following SNP and sample quality control, we analysed a total of 187,951 genetic 
variants in 579 cases of non-infectious and non-anterior uveitis and 3,676 controls of 
European ancestry. 
As shown in Figure 1, two signals reached the established significance threshold 
(1.14x10-6) in the inverse-variance meta-analysis including the three cohorts. These 
peaks lied within the HLA region and the chromosomal region 2q11.2.  
 
HLA associations 
After imputation, a high association peak was observed within the HLA class I region 
(Supplementary Figure 1). Specifically, the top associated signal belonged to the 
classical allele HLA-A*2902 (p=1.04E-16, OR=2.41). The strong association between 
this HLA allele and BSCR is well established,33 and many patients with this condition 
(n=78/579) were included in our analysis. Therefore, in order to determine whether this 
signal was due to a strong association with the BSCR subgroup of patients, we decided 
to further stratify our analyses of the HLA region by considering the BSCR patients on 
one hand and the remaining uveitis patients on the other hand. 
HLA analyses in the subgroup of patients with BSRC. When BSRC patients were 
independently analyzed, a stronger association between the classical allele HLA-
A*2902 and this disease was evident (p=3.21E-35, OR=50.95) (Figure 2 and 
Supplementary Table 3). Although several SNPs, linked to this classical allele, also 
showed strong associations, HLA-A*2902 had the greatest effect size (Supplementary 
Table 3). Signals within the HLA-B, -C and class II regions were also observed; 
however, no independent secondary effects were found after controlling for the effect of 
HLA-A*2902 (Figure 2 and Supplementary Table 3). 
Subsequently, we examined whether a specific amino acid position could be 
responsible for the association observed for this classical allele by means of an 
omnibus test (Supplementary Figure 2 and Supplementary Table 4). The most 
relevant amino acid positions for disease risk were the positions 63 and 62 of the HLA-
A molecule (PLRT=1.44E-58 and PLRT=3.99E-57, respectively). After performing the 
omnibus test conditioning on either of these two polymorphic positions, none of the 
other signals remained significant (Supplementary Figure 2 and Supplementary 
Table 4).  
Table 1 shows the most associated amino acid residues in both positions, Leu in 
position 62 and Gln in position 63 (p=5.33E-35, OR=49.48), which are in complete LD. 
Both residues showed statistically nearly indistinguishable effects compared to the 
classical allele HLA-A*2902 (OR=50.95). When we performed a logistic regression 
analysis adjusting for HLA-A*2902, the association of Leu-62/Gln-63 with BSCR was 
lost (p=0.111). Similarly, after controlling for either of these two residues, the 
association between HLA-A*2902 and BSCR also lost its statistical significance 
(p=0.294) (Figure 2 and Supplementary Table 3). 
HLA analyses in non-infectious non-anterior uveitis patients excluding BSCR. 
Subsequently, we considered the remaining uveitis patients who did not have BSRC 
(n=503) (Supplementary Figure 3 and Supplementary Table 5). No signals in the 
class I region were observed, thus indicating that the association between HLA-A*2902 
and uveitis observed in our initial analysis was due to the strong association of this 
allele with BSCR. However, a peak within the HLA class II region was evident, with a 
set of SNPs, located within the HLA-DRA gene and in close LD, showing the strongest 
signal (highest hit rs3129888: p=6.33E-09, OR=1.65) (Supplementary Figure 3 and 
Supplementary Table 5). Additionally, these SNPs were strongly linked to the 
classical alleles forming the HLA-DR15 haplotype, DRB1*1501, DQA1*0102 and 
DQB1*0602, which also appeared to be associated with disease (p=3.23E-08, 
OR=1.72; p=6.86E-08, OR=1.57; and p=3.03E-08, OR=1.73, respectively).  
Since an association between the DR15 haplotype and idiopathic intermediate uveitis 
has been reported previously,34 35 we reanalysed the HLA region stratifying patients 
according to the anatomical location of their inflammation (Supplementary Figure 4). 
In the group of patients with intermediate uveitis (n=154), a peak within the HLA class II 
region was observed, although no significant associations were found. The largest 
signals corresponded to the set of SNPs located within HLA-DRA (highest hit rs7197: 
p=8.91E-05, OR=1.78). As previously described, the classical alleles DRB1*1501, 
DQA1*0102 and DQB1*0602, also appeared between the most significant variants 
(p=8.92-04, OR=1.72; p=9.26E-04, OR=1.58; and p=2.06E-03, OR=1.67, respectively). 
Interestingly, when we analyzed the group of patients with posterior uveitis (n=194), a 
similar pattern was evident. Again, the highest signals arose from DRA polymorphisms 
(highest hit rs3135388: p=2.06E-09, OR=2.38) and the DRB1*1501 (p=2.93E-09, 
OR=2.36) and DQB1*0602 (p=8.08E-09, OR=2.30) alleles. Indeed, in this subgroup of 
patients, these class II signals reached the genome-wide significance level.  
Finally, when we analyzed the last subgroup of uveitis patients, those with panuveitis 
(n=141), we did not observe any peak within the HLA region. 
HLA analyses in patients with intermediate and posterior uveitis. Since a similar 
pattern of association between HLA-DR and -DQ alleles and either intermediate and 
posterior uveitis was observed, we next combined both subgroup of patients to better 
define the association between this HLA region and these clinical phenotypes. As 
expected, the strongest signals corresponded to HLA-DRA variants (highest hit rs7197: 
p=2.07E-11, OR=1.99) and the HLA-DRB1*1501 classical allele (p=1.16E-10, 
OR=2.08) (Figure 3 and Supplementary Table 6). We next carried out a step-wise 
conditional logistic regression analysis to identify HLA alleles that independently 
influenced the susceptibility. No additional independent associations were observed 
after conditioning on either of the top signals, rs7197 or DRB1*1501 (Figure 3 and 
Supplementary Table 6). 
After performing the omnibus test, the positions 133 and 142 of the HLA-DRβ1 
molecule (which are completely linked) appeared to be the most associated with 
posterior and intermediate uveitis (PLRT=1.64E-09) (Supplementary Figure 5 and 
Supplementary Table 7). All the remaining associated positions were explained by 
linkage to HLA-DRβ1 133/142 after performing the conditioned omnibus test 
(Supplementary Figure 5 and Supplementary Table 7). 
Table 2 shows the most associated amino acid residues with intermediate and 
posterior uveitis. Positions 133 and 142 were biallelic in the analysed cohort, with two 
possible amino acid residues present at each of them, leucine and arginine in position 
133 and valine and methionine in position 142. Of these, Leu-133 and Met-142 
appeared to confer risk to the disease (p=4.79E-10, OR=1.94). Interestingly, these 
amino acids correlated with two other residues of the HLA-DRβ molecule, proline in 
position 11 and arginine in position 13 (Table 2). Therefore, the conditional analysis 
adjusting for each of the amino acid residues (Leu-133, Met-142, Pro-11 or Arg-13) 
could not statistically distinguish which of them was driving the effect. 
Finally, functional annotation analysis indicated that most of the SNPs linked to the 
HLA-DRA gene (including the SNP with the strongest association, rs7197) have a 
regulatory role in immune cell lines, modulating the expression of a large number of 
genes, including DRB1 and DQB1 (Supplementary Table 8). 
 
Non-HLA associations 
Outside the HLA region, a novel signal was observed in chromosome 2q11.2 (Figure 
1). The rs7608679 genetic variant, located in an intergenic region between the 
MAP4K4 (mitogen-activated protein kinase kinase kinase kinase 4) and IL1R2 
(interleukin 1 receptor type 2) genes, reached the established significance threshold in 
the meta-analysis (p=8.38E-07, OR=1.42) (Table 3). In addition, several other genetic 
variants in tight LD with it also showed strong associations. However, stepwise logistic 
regression analyses, conditioned on the most highly associated polymorphism, showed 
there were no other variants with independent effects (Supplementary Figure 6). 
When we evaluated the potential regulatory role of rs7608679 and its proxies, several 
SNPs (rs13011687, rs12473090, rs12990046 and rs1541435) overlapped with histone 
marks enriched at promoters and enhancers in different immune cell lines (monocytes, 
neutrophils and primary B cells) (Supplementary Table 9). Furthermore, all of them 
appeared to influence the expression levels of both the IL1R2 and the MAP4K4 genes 
in whole blood (PMID: 24013639).  
Finally, we also evaluated signals reaching our suggestive tier of association (2.29x10-
5). Genetic variants in five regions passed this statistical threshold (Figure 1 and Table 
3). The third strongest signal belonged to a SNP (rs76649453) in an intronic region of 
the KIAA1109 locus (p=4.07E-06, OR=2.31). This gene, located within a large 
haplotype block encompassing the autoimmunity-associated genes IL2 and IL21, has 
been previously associated with BD 36. Suggestive associations were also found for 
SNPs in close proximity to RCL1/JAK2 (RNA terminal phosphate cyclase like 1/janus 
kinase 2) (rs7862852: p=8.82E-06, OR=1.35), CASP10/TRAK2 (caspase 10/trafficking 
kinesin protein 2) (rs17672977: p=1.02E-05, OR=2.07), ERC2 (ELKS/RAB6-
interacting/CAST family member 2) (rs13098621: p=1.23E-05, OR=1.50) and 
HHEX/EXOC6 (hematopoietically expressed homeobox/exocyst complex component 
6) (rs11187157: p=1.96E-05, OR=1.33). 
For all these loci, except for ERC2, the top associated SNPs, or those showing high LD 
with them (r2> 0.8), seemed to have potential functional roles (Supplementary Table 
9). Enrichment for histone marks, Dnase hypersensitive sites and/or eQTLs were 
evident using publicly available functional annotation data. Interestingly, the lead SNP 
within the HHEX/EXOC6 region influenced gene expression levels of EXOC6 in 
dendritic cells (PMID: 22233810) and KIF11 (kinesin family member 11) in lung (PMID: 
25954001). Regarding CASP10/TRAK2, several proxy SNPs correlated with the 
expression in lymphoblastoid cell lines (PMID: 24037378) of two genes located in the 
same haplotype block, CFLAR (CASP8 and FADD like apoptosis regulator) and PPIL3 
(peptidylprolyl isomerase like 3). Finally, the associated SNP within the RCL1/JAK2 
locus was highly correlated with the expression of JAK2 in whole blood (PMID: 
24013639).  
DISCUSSION 
By conducting the first large-scale genotyping study in non-infectious uveitis, we have 
confirmed the HLA locus as the most strongly associated region with this inflammatory 
condition. We have explored subphenotype associations, both shedding light into the 
previously reported HLA signals and identifying possible mechanisms by which these 
molecules are involved in the development of uveitis. Furthermore, outside the HLA 
region, we have detected a new risk locus, MAP4K4/IL1R2, and five suggestive 
associations with KIAA1109, RCL1/JAK2, CASP10/TRAK2, ERC2 and HHEX/EXOC6. 
The correlation between BSCR and the classical allele HLA-A*2902 represents one of 
the strongest associations between the HLA region and disease reported to date.33 In 
this regard, our results suggest that this effect could be driven by the amino acid 
Leu62/Gln63. Indeed, in our study cohort, both residues, Leu62 and Gln63, are specific 
to the classical alleles HLA-A*2902 and *2901. The lack of association between HLA-
A*2901 and BSCR in our dataset (p=0.201) was probably due to the lower frequency of 
this classical allele (0.002) compared with HLA-A*2902 (0.057). Indeed, a nominal 
association between HLA-A*2901 and BSCR was reported in a previous GWAS20 (in 
which part of the BSCR samples overlapped with those included in the present study). 
It should be noted that the amino acid positions 62 and 63 of the HLA-A protein are 
likely to be involved in the antigen presentation process. On one hand, the position 62 
within the antigen binding site is positioned to make direct contact with the T cell 
receptor,37 whereas the position 63 faces into the antigen binding site and is likely to be 
involved in peptide binding.37 38 Therefore, these amino acid positions could be 
responsible for the effect of the HLA-A molecule on the BSCR susceptibility. 
Our study confirms the previously reported association between the HLA-DR15 
haplotype and idiopathic intermediate uveitis.34 35 Interestingly, this haplotype 
represents the primary HLA genetic susceptibility factor for multiple sclerosis (MS),39 an 
immune-mediated disease often associated with intermediate uveitis.40 However, our 
data revealed for first time that the classical alleles forming this haplotype (DRB1*1501, 
DQA1*0102 and DQB1*0602) have an even stronger influence on susceptibility to 
posterior uveitis compared with the intermediate form of the disease. The combined 
analysis of both intermediate and posterior uveitis patients pointed toward positions 
133 and 142 of the HLA-DRβ1 molecule as the most relevant for disease susceptibility. 
None of these positions have been reported to be involved in antigen presentation; 
however, amino acid residues conferring risk to the disease (Leu-133 and Met-142) 
were almost completely linked to Pro-11 and Arg-13. Both proxy positions lie within the 
peptide binding groove of the HLA-DR molecule and therefore, a functional role can be 
more reliably ascribed to them. Indeed, these same amino acid positions have been 
reported to be the most relevant for SLE susceptibility.41 Additionally, a previous fine-
mapping of the HLA region in MS identified the position 71 of DRβ1 as the most 
significant conferring risk.42 This is also located in the peptide groove of the HLA-DR 
molecule and is tightly correlated with positions 11 and 13 (r2=0.90). Indeed, in our 
dataset, the amino acid alanine in position 71 also showed high statistical significance, 
as shown in Supplementary Table 6.  
On the other hand, the highest signals associated to intermediate and posterior uveitis 
belonged to a set of highly linked genetic variants located in the HLA-DRA gene. Many 
of these SNPs appeared to act as eQTLs affecting the expression levels of a number of 
genes, some of which encodes HLA molecules, such as DQB1 and DRB1. Therefore, a 
potential functional effect of these polymorphisms on the pathogenesis of posterior and 
intermediate uveitis cannot be discounted. In this instance, polymorphisms of the HLA 
region in this subgroup of patients could be altering the expression of certain genes 
rather than directly influencing the antigen presentation process. Nevertheless, the high 
LD between the associated SNPs, classical alleles and amino acid residues makes it 
difficult to determine the true causal variant.  
Outside the HLA region, we identified the MAP4K4/IL1R2 locus as a new genetic risk 
factor for non-infectious non-anterior uveitis. In silico eQTL analysis showed several 
proxy SNPs affecting the expression levels of these two genes in whole blood. 
MAP4K4 encodes a member of the serine/threonine protein kinase family, which is 
involved in the tumour necrosis factor-alpha (TNF-α) signalling pathway, whereas 
IL1R2 encodes a cytokine receptor that inhibits the activity of its ligands (IL-1A, IL-1B 
and IL1R1). Both proinflammatory cytokines, TNF-α and IL-1, have been detected in 
the eye during active inflammation.43 Interestingly, two recent clinical trials have 
demonstrated an effective response to adalimumab treatment, a TNF-α inhibitor, in 
patients with non-infectious intermediate, posterior, or panuveitis.44 45 Similarly, 
treatment with gevokizumab, a monoclonal antibody inhibiting the activation of IL-1 
receptors, has also shown therapeutic efficacy in patients with Behçet’s disease 
uveitis.46 Moreover, this region has been previously associated with ankylosing 
spondylitis (AS),47 an inflammatory disorder that frequently presents acute anterior 
uveitis (30-40% of AS patients).  
Evidence for eQTLs was found for three of the five loci showing suggestive 
associations with uveitis and may help annotate these signals. In this regard, the 
association observed in the HHEX/EXOC6 region seemed to be due to an eQTL 
influencing the expression of EXOC6 and KIF11. EXOC6 is one of three genes 
included in a chromosomal microdeletion leading to an autosomal dominant form of 
non-syndromic optic nerve aplasia;48 whereas mutations in KIF11 cause an autosomal 
dominant disorder characterised by chorioretinopathy.49 SNPs within the 
CASP10/TRAK2 locus were found to affect the expression of two genes located in the 
same haplotype block; CFLAR, a regulator of apoptosis, and PPIL3, involved in protein 
folding. Finally, eQTL analysis showed that JAK2 was the most likely causal gene 
within the RCL1/JAK2 locus. JAK2 encodes a signal transducer that plays an important 
role in the differentiation of Th1 and Th17 lymphocytes and both cell types are heavily 
implicated in the pathogenesis of autoimmune uveitis.50 
In summary, our study has revealed new associations with non-infectious uveitis, both 
within and outside the HLA region, thus shedding light into the pathogenesis of this 
condition. Our results highlight the existence of common molecular mechanisms, such 
as the TNF-α or IL-1 signalling, influencing the pathophysiology of the different uveitic 
entities. The identification of genetic pathways implicated in these disorders will lead to 
more specific and effective therapeutic procedures. 
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Table 1. Amino acid residues of the HLA-A molecule showing the strongest associations with birdshot chorioretinopathy. 
   
Residue frequency Meta-analysis Spain Netherlands 
Amino acid 
residue 
Binding 
Pocket 
Classical 
HLA Alleles 
Birdshot Controls P-value OR [95% CI] P-value OR [95% CI] P-value OR [95% CI] 
Leu62 Yes 
*29:01 and 
*2902 
0.519 0.059 5.33E-35 49.48 [26.63-91.93] 3.22E-21 25.56 [13.05-50.03] 1.08E-12 219.20 [49.72-966.80] 
Gln63 Yes 
OR, odds ratio; CI, confidence interval. 
 
 
 
 
 
 
 
 
Table 2. Amino acid residues of the HLA-DRβ1 molecule showing the strongest associations with intermediate and posterior uveitis.  
 
    
Residue 
frequency 
Meta-analysis Spain Netherlands UK 
Amino acid 
residue 
Binding 
pocket 
r2 with Pro11 
Classical HLA 
alleles 
IU+PU Controls P-value OR [95% CI] P-value OR [95% CI] P-value OR [95% CI] P-value OR [95% CI] 
Pro11 Yes NA 
15:01, 15:02 
and 15:03 
0.210 0.131 4.43E-10 1.94 [1.58-2.40] 5.12E-09 2.26 [1.72-2.98] 0.091 1.53 [0.93-2.49] 0.015 1.75 [1.12-2.75] 
Arg13 Yes 1 0.210 0.131 4.43E-10 1.94 [1.58-2.40] 5.12E-09 2.26 [1.72-2.98] 0.091 1.53 [0.93-2.49] 0.015 1.75 [1.12-2.75] 
Leu133 No 0.995 0.210 0.132 4.79E-10 1.94 [1.58-2.39] 5.55E-09 2.26 [1.72-2.97] 0.090 1.53 [0.94-2.49] 0.016 1.74 [1.11-2.74] 
Met142 No 0.995 0.210 0.132 4.79E-10 1.94 [1.58-2.39] 5.55E-09 2.26 [1.72-2.97] 0.090 1.53 [0.94-2.49] 0.016 1.74 [1.11-2.74] 
NA, not applicable; OR, odds ratio; CI, confidence interval; IU, intermediate uveitis; PU, posterior uveitis. 
 
Table 3. Non-HLA loci associated with non-infectious non-anterior uveitis at the established significance level (p<1.14×10−6) (bold) and at the 
suggestive significance level (p<2.29×10−5). 
     
Allele frequency 
  
    
Spain Netherlands UK Meta-analysis 
Chromosome Loci Most significant SNP Minor allele Uveitis Controls Uveitis Controls Uveitis Controls P-value OR [95% CI] 
2 MAP4K4 / IL1R2 rs7608679 C 0.301 0.234 0.357 0.240 0.277 0.246 8.38E-07 1.42 [1.23-1.63] 
4 KIAA1109 rs76649453 A 0.047 0.018 0.040 0.020 0.027 0.015 4.07E-06 2.31 [1.62-3.31] 
9 RCL1/JAK2 rs7862852 C 0.388 0.327 0.401 0.375 0.464 0.346 8.82E-06 1.35 [1.18-1.54] 
2 CASP10/TRAK2 rs17672977 G 0.033 0.020 0.075 0.033 0.055 0.024 1.02E-05 2.07 [1.50-2.87] 
3 ERC2 rs13098621 A 0.160 0.108 0.147 0.102 0.150 0.115 1.23E-05 1.50 [1.25-1.79] 
10 HHEX/EXOC6 rs11187157 C 0.442 0.388 0.528 0.445 0.509 0.448 1.96E-05 1.33 [1.17-1.51] 
OR, odds ratio; CI, confidence interval. 
 
 
FIGURE LEGENDS 
Figure 1. Manhattan plot of the meta-analysis of the three analysed cohorts. The red 
and blue lines represent the established (p=1.14×10−6) and the suggestive 
(p=2.29×10−5) significance levels, respectively.  
 
 
 
  
Figure 2. Manhattan plot representing the results of the conditional logistic regression 
analysis of the HLA region in patients with birdshot chorioretinopathy. (A) 
Unconditioned test of the HLA region. (B) Results after conditioning on the HLA-A*2902 
classical allele. (C) Results after conditioning on the amino acid residue Leu62/Gln63. 
The red/green color gradient represents the effect direction of each analyzed variant 
(red for risk and green for protection). The size of the diamonds indicates the degree of 
linkage disequilibrium with the classical allele HLA-A*2902. The red line represents the 
established significance threshold (p<1.14x10-6). 
 
 
  
Figure 3. Manhattan plot representing the results of the conditional logistic regression 
analysis of the HLA region in patients with posterior and intermediate uveitis. (A) 
Unconditioned test of the HLA region. (B) Results after conditioning on the rs7197 
polymorphism. (C) Results after conditioning on the HLA-DRB1*1501 classical allele. 
The red/green color gradient represents the effect direction of each analyzed variant 
(red for risk and green for protection). The size of the diamonds indicates the degree of 
linkage disequilibrium with the classical allele HLA-DRB1*1501. The red line represents 
the established significance threshold (p<1.14x10-6). 
 
 
